Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
An extended multi-year semiconductor advanced packaging and artificial intelligence hardware deployment cycle driving structural demand for ultra-precise ATS dispensing and acoustic inspection systems, paired with rapid global scaling of Medical and Fluid Solutions disposables,.
Nordson Corporation (NDSN) is a premier industrial precision dispensing and fluid management compounder, but current share prices have dissociated from fundamental valuation. Trading at $328.17 as of 2026-10-09 against a synthesized committee Fair value of $206.83, the stock carries an implied return of -36.97% and trades at an extreme 58.67% premium to intrinsic worth, establishing a clear Sell rating.3
Nordson Corporation exhibits textbook compounder attributes: mission-critical precision dispensing solutions that represent a fraction of customer factory capex but dictate manufacturing yields, creating powerful switching barriers and recurring aftermarket revenues. In FY2025, consolidated operating income reached $711.73M on $2,791.69M of sales (25.49% operating margin),, while cash generation proved exceptional with of $661.12M, converting 136.5% of GAAP ($484.47M) on modest capex of $58.06M.
In Q3 2026, operational execution remained outstanding, with organic revenue growing 12% YoY, sales reaching a record $818M, and order backlog expanding by 35% YoY across all operating segments without lead time elongation,. Management subsequently raised FY2026 guidance to sales of $3.04B-$3.08B and adjusted EPS of $11.80-$12.00,, fully adopted in our forecast and aligned with consensus estimates ($3,057.30M sales, $11.95 EPS),.14
Despite these stellar operational credentials, the investment thesis is overwhelmingly dominated by valuation risk. At $328.17 per share, the equity commands a forward P/E of 24.75x, standing far above industrial peers such as OTIS (14.57x) and GNRC (17.34x). Capital preservation mandates a Sell rating, as any cyclical pause in semiconductor packaging capex or margin friction will trigger severe multiple compression.3
Mission-critical dispensing applications represent a negligible fraction of manufacturing capex but govern assembly yields, entrenching customer switching costs and sustaining 25%+ operating margins and strong consumable sales,.47
Deployment of NBS Next has systematically reduced cycle times and elevated on-time delivery, allowing Nordson to win competitive bids against peers and convert a 35% backlog surge without fulfillment delays,.4
Dispensing equipment represents a fractional percentage of total factory capex but controls vital process integrity, resulting in severe customer switching barriers and high-margin recurring parts consumption. Core Industrial Precision Solutions generated $1,331.79M in FY2025 revenue (47.7% of total sales), anchored by proprietary consumable nozzles and close-to-customer integration.47
Sell. Nordson is an exceptional industrial compounder whose stock price ($328.17) has dramatically overshot its intrinsic value ($206.83). Investors should systematically harvest gains and exit positions.3
Nordson Corporation designs, manufactures, and markets precision dispensing, fluid management, and test and inspection systems utilized in industrial manufacturing, consumer electronics packaging, and medical applications. The company operates through three core reporting segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS),,. In FY2025, consolidated revenue totaled $2,791.69M, with IPS contributing $1,331.79M (47.7%), MFS contributing $835.39M (29.9%), and ATS contributing $624.51M (22.4%).
Geographically, Nordson maintains balanced revenue diversification across the Americas ($1,205.83M, 43.2%, including $922.73M from the United States),, Asia-Pacific excluding Japan ($863.64M, 30.9%), and Europe ($722.22M, 25.9%). The business model is supported by a global direct sales and technical service organization operating under the NBS Next operational framework, driving high recurring parts consumption and superior delivery lead times,.
Under a synchronized industrial and electronics downcycle realization, severe pressure materializes across Nordson's operating structure. In this stress case, cyclical retrenchment in electronics packaging slashes ATS revenue by 15% YoY while price/cost friction and industrial customer capex deferrals compress consolidated operating margins from 25.49% down to 22.5%. This decelerates 3-year EPS CAGR to 4.5% and de-rates the terminal valuation multiple to 17.0x P/E, driving discounted cash flow equity value toward $142.03 per share and yielding a bear case fair value floor of $173.06. Given the share price of $328.17 as of 2026-10-09, an investor entering at market levels faces a severe 47.3% potential capital impairment under stress realization.
ATS generated $624.51M in FY2025 revenue. While management noted strong packaging demand in Q3 2026, a sharp downturn in advanced packaging test and inspection would slash high-margin equipment shipments and trigger cancellations across the six-month backlog, impairing fair value by 28.5%.47
The five developments that would weaken our investment case.
A sudden contraction in semiconductor advanced packaging test and inspection demand triggering equipment shipment pushouts across the six-month backlog.
Current:10% overall YoY sales growth and 35% backlog expansion in Q3 2026
Alert ifATS quarterly revenue contraction exceeding 15% YoY
Nordson Corporation possesses a Narrow economic moat grounded in mission-critical precision dispensing equipment, proprietary micro-fluid control technologies, and extensive customer switching costs. Across industrial assembly, semiconductor advanced packaging, and medical fluid delivery, Nordson's products constitute a small portion of a customer's total manufacturing capital expenditure, yet govern essential manufacturing yields and component reliability. Replacing Nordson dispensing heads, inspection cameras, or fluid valves introduces unacceptable production stoppage and validation failure risks, resulting in entrenched customer relationships and recurring consumable parts purchases.
This switching-cost foundation is most visible in Industrial Precision Solutions (IPS), which generated $1,331.79M in FY2025 revenue, contributing 47.7% of consolidated sales ($2,791.69M) and supporting an operating margin of 25.49%. The company's Ascend Strategy and NBS Next framework enhance this competitive advantage by systematically reducing manufacturing lead times below industrial peers, driving competitive market share gains without internal delivery bottlenecks.
However, the moat is constrained to a Narrow rating due to capital equipment cyclicality in Advanced Technology Systems ($624.51M FY2025 revenue) and vulnerability to price/cost friction during industrial downcycles, as observed in historical margin compressions to 16.48% in FY2020 and Q3 2026 IPS margin softness. While structural advantages protect economic profits above cost of capital over a 10-year horizon, they do not shield the equity from severe multiple de-rating when market valuation extends far beyond intrinsic earning power.
Nordson generates consistent economic profit well above its cost of capital. In FY2025, operating income reached $711.73M on $2,791.69M of revenue (25.49% operating margin),, producing net income of $484.47M and return on invested capital of approximately 11.97%, compared to a corporate WACC of 8.86% and cost of equity of 9.27%. However, with shares trading at $328.17, the equity market prices in perpetual economic rent extraction far above intrinsic value.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($206.83). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $530.4M after modeled reinvestment of $116.4M, with terminal value at 76.3% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base scenario carries a probability of 60.0% and establishes a target valuation of $206.83, implying a projected return of -37.0% relative to $328.17. This path assumes that precision dispensing demand remains steady across industrial manufacturing and that order backlog converts cleanly over an operational turnover horizon without supply disruptions. Operating margins expand gradually as operational efficiencies under NBS Next offset moderate price and cost pressures. Disconfirmation would emerge if quarterly order intake slows or if incremental margins fail to meet management expectations, signaling competitive share losses or end-market softening.
A quarterly beat confirms that operational execution under NBS Next and semiconductor packaging demand remain robust. However, because $328.17 trades at a substantial premium above Fair value $206.83, operational outperformance does not bridge the wide valuation deficit.
Results meeting guided expectations demonstrate steady operations but leave the substantial valuation premium above Fair value $206.83 unaddressed, preserving negative expected return asymmetry from $328.17.
An operational miss validates cyclical vulnerability in electronics packaging equipment or margin dilution from input costs, triggering sharp valuation multiple compression toward industrial peer medians.
Nordson exhibits high operational earnings quality characterized by robust free cash conversion that consistently matches reported net income. Operating margins reflect proprietary dispensing technology and pricing discipline, while high recurring consumable parts sales provide revenue resilience across manufacturing cycles. Working capital remains disciplined under the NBS Next operational architecture, with inventory turnover and receivables aligning cleanly with customer delivery schedules. Reported results are free from aggressive non-operational adjustments, ensuring reported earnings accurately reflect core business performance.
Consensus analyst earnings revisions have remained largely flat following the recent earnings release, with minor cohort adjustments incorporating raised management guidance ranges. While full-year revenue and adjusted earnings guidance were increased to reflect strong order backlog execution, outyear projections maintain a balanced expectation of normalization in semiconductor packaging equipment demand and steady organic expansion in medical fluid solutions.
Advanced packaging dispense and inspection equipment orders represent the primary cyclical swing factor for top-line revenue and high-margin mix, directly dictating operating leverage.
Nordson exhibits stellar cash conversion. In FY2025, the company generated $719.18M in operating cash flow and expended only $58.06M on capital expenditures, yielding free cash flow of $661.12M. This represents an outstanding 136.5% free cash flow conversion of GAAP net income ($484.47M). High cash conversion is sustained by mission-critical parts revenue, disciplined working capital management under NBS Next, and low capital intensity.56
Nordson delivers stable, high economic profit over invested capital, demonstrating that proprietary fluid dispense systems and mission-critical components generate sustainable economic rents. This return profile easily exceeds industrial sector benchmarks, reflecting strong installed base monetization and low ongoing maintenance capex requirements.
ROIC of approximately 11.97% exceeds the corporate WACC of 8.86% by over 310 basis points, generating consistent economic value above capital costs.
Operating cash flow of $719.18M against capex of $58.06M generated $661.12M of free cash flow in FY2025, exceeding of $484.47M.
| Revenue | $2,791,687,000 |
|---|---|
| Cost of revenue | $1,251,903,000 |
| Gross profit | $1,539,784,000 |
| Operating expenses | $828,059,000 |
| Operating income | $711,725,000 |
| Non-operating items and tax | -$227,251,000 |
| Net income | $484,474,000 |
| Total assets | $5,917,681,000 |
|---|---|
| Cash | $108,442,000 |
| Current assets | $1,242,851,000 |
| Total liabilities | $2,874,110,000 |
| Current liabilities | $758,260,000 |
| Shareholders’ equity | $3,043,571,000 |
| Net income | $484,474,000 |
|---|---|
| Operating inflow | $719,175,000 |
| Depreciation and amortization | $79,264,000 |
| Stock-based compensation | $18,944,000 |
| Other operating adjustments | $136,493,000 |
| Operating cash flow | $719,175,000 |
| Cash available | $841,563,000 |
| Beginning cash | $115,952,000 |
| Exchange-rate effect | $6,436,000 |
| Investing outflow | $26,690,000 |
| Financing outflow | $706,431,000 |
| Ending cash | $108,442,000 |
| Investing cash flow | -$26,690,000 |
| Financing cash flow | -$706,431,000 |
Source: SEC EDGAR · Filed 2025-12-17 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Industrial Precisions Solutions | $1.3B | 47.7% | -4.8% |
| Medical Fluid Systems | $835.4M | 29.9% | 20.1% |
| Advanced Technology Systems | $624.5M | 22.4% | 4.9% |
Point-in-time financial data used in the 2026-10-11 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-10-31 | $1.8B | $460.1M | $271.8M | $334.6M | $273.8M | $60.9M | $70.3M | $18.2M | $33.4M | $56.4M | — | -$102.2M | -$213.8M | — | $67.2M | $67.2M | $980.9M | 21.5% | — | 6.1% | — |
| 2017-10-31 | $2.1B | $547.7M | $295.8M | $356.8M | $285.2M | $71.6M | $90.9M | $20.2M | $3.2M | $63.8M | — | -$878M | $540.8M | $67.2M | $90.4M | $90.4M | $1.6B | 22.6% | — | 6.9% | — |
| 2018-10-31 | $2.3B | $606.5M | $377.4M | $504.6M | $414.8M | $89.8M | $108.4M | $21.6M | $24M | $72.4M | — | -$139.9M | -$353.7M | $90.4M | $95.7M | $95.7M | $1.3B | 22.3% | — | 7.7% | — |
| 2019-10-31 | $2.2B | $588.5M | $337.1M | $382.9M | $318.6M | $64.2M | $110.2M | $18.1M | $120.5M | $82.1M | — | -$76.3M | -$251.1M | $95.7M | $151.2M | $151.2M | $1.2B | 22.0% | — | 6.5% | — |
| 2020-10-31 | $2.1B | $447M | $249.5M | $502.4M | $451.9M | $50.5M | $113.3M | $12.9M | $52.6M | $88.3M | — | -$194.1M | -$251.5M | $151.2M | $208.3M | $208.3M | $1.1B | 16.5% | — | 5.0% | — |
| 2021-10-31 | $2.4B | $703.6M | $454.4M | $545.9M | $507.6M | $38.3M | $103.9M | $22.8M | $61M | $97.7M | — | -$33.2M | -$422.9M | $208.3M | $300M | $300M | $812.4M | 26.0% | — | 5.5% | — |
| 2022-10-31 | $2.6B | $771.6M | $513.1M | $513.1M | $461.7M | $51.4M | $99.9M | $30.7M | $262.9M | $125.9M | -$39.3M | -$222.8M | -$416M | $300M | $163.5M | $163.5M | $737.9M | 27.1% | — | 7.9% | — |
| 2023-10-31 | $2.6B | $786.7M | $487.5M | $641.3M | $606.7M | $34.6M | $59.7M | $22.7M | $89.7M | $150.4M | $969.2M | -$1.4B | $750.5M | $163.5M | $115.7M | $115.7M | $1.7B | 25.6% | — | 8.4% | — |
| 2024-10-31 | $2.7B | $810.6M | $467.3M | $556.2M | $491.8M | $64.4M | $77M | $19M | $33.3M | $161.4M | $458.2M | -$844.4M | $294.5M | $115.7M | $116M | $116M | $2.2B | 25.1% | — | 7.5% | — |
| 2025-10-31 | $2.8B | $849.3M | $484.5M | $719.2M | $661.1M | $58.1M | $79.3M | $18.9M | $306.4M | $179.1M | -$230M | -$26.7M | -$706.4M | $116M | $108.4M | $108.4M | $2B | 25.5% | — | 7.6% | — |
Nordson Corporation (NDSN) trades at 24.8x forward earnings against a peer median of 19.4x. Its EV/EBITDA of 20.8x compares with a peer median of 20.1x. The comparison uses 4 peers: Otis Worldwide Corporation, Rockwell Automation Inc., Illinois Tool Works Inc. and Generac Holdings Inc., as of 2026-10-11.
The industrial machinery benchmark exhibits a capex-to-revenue ratio of 4.1% and a capex-to-depreciation ratio of 0.68 as of 2026-10-05, reflecting mature, disciplined reinvestment across the sector. Nordson operates with even lower capital intensity, reinvesting $58.06M in capex against $2,791.69M of revenue (2.08% capex/revenue),, while converting order backlogs that surged 35% YoY in Q3 2026.46
Accelerating global demand for semiconductor advanced packaging test and dispense equipment, combined with rising penetration of medical fluid components, drives order intake above six-month backlog turnover rates, sustaining 12% organic sales growth and expanding incremental margins toward 40%.
Electronics assembly capex pauses as customer capacity catches up, leading to order cancellations across the six-month backlog, slashing high-margin ATS equipment shipments, and exposing the company to cyclical operating margin dilution down toward historical trough levels (16.48% in FY2020).
Nordson is exceptionally positioned at the high end of industrial manufacturing profitability. With consolidated operating margins of 25.49% and gross margins exceeding 55%, Nordson dramatically outperforms broader industrial sector medians (operating margin of 16.1% and gross margin of 37.5%). Shorter lead times and superior on-time delivery under NBS Next allow the company to capture profitable market share during cyclical upswings without incurring internal capacity bottlenecks.46
With the stock trading at $328.17 as of 2026-10-09, standing at an extreme 58.67% premium over committee Fair value of $206.83, capital preservation requires zero equity exposure. The Sell rating reflects an implied return of -36.97% and severe downside asymmetry.3
Risk management requires strict adherence to the committee Sell rating. Investors holding NDSN equity should execute phased limit orders into market strength to eliminate position exposure. Chasing momentum near 52-week highs ($339.12) entails severe drawdown vulnerability, as the market multiple of 24.75x forward P/E leaves no margin for cyclical normalization in electronics packaging. Risk can be hedged via out-of-the-money put options or paired relative-value positions against lower-multiple diversified industrial peers.
With the shares trading at $328.17 against a synthesized Fair value of $206.83, there is zero margin of safety; value investors should avoid the stock until a substantial valuation correction occurs.3
Even though Nordson possesses narrow-moat switching costs and high cash conversion, paying a 58.67% premium to intrinsic worth severely impairs multi-year compounding returns.2
With forward P/E at 24.75x and the stock near 52-week highs ($339.12), upside momentum is largely exhausted and asymmetric downside risk looms if order backlog growth normalizes.3
Nordson Corporation is rated Sell based on a committee Fair value of $206.83 compared to the share price of $328.17 as of 2026-10-09, representing an implied return of -36.97% and an excessive 58.67% price premium over intrinsic worth.3
While Nordson operates an exceptional precision dispensing franchise with durable switching costs, superior free cash flow conversion, and disciplined NBS Next execution, prevailing market multiples of 24.75x forward P/E provide zero margin of safety and leave shareholders highly exposed to cyclical mean reversion.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
The Bear scenario contemplates a synchronized cyclical pullback in electronics manufacturing coupled with broader industrial stagnation across international markets. Under this trajectory, customer deferrals of advanced packaging line installations lead to cancellations across the order backlog, slashing high-margin equipment shipments. Concurrently, competitive pricing pressures and product mix dilution compress operating margins toward historical trough levels, triggering a valuation multiple contraction toward diversified industrial peer medians. Disconfirmation would occur if quarterly order intake remains resilient and book-to-bill ratios remain above parity throughout consecutive reporting cycles.
While FY2025 operating margin was 25.49% and management targets 35-40% incremental margins, historical margins dropped to 16.48% in FY2020. In Q3 2026, IPS margins contracted year-over-year from price/cost dynamics. A sustained price-cost squeeze lowering operating margins below 22.5% reduces fair value by 24.0%.46
Nordson trades at 24.75x forward P/E, compared to peers OTIS at 14.57x and GNRC at 17.34x. If organic revenue growth slows below 4.5%, the valuation premium to peers would contract toward the bear case terminal P/E of 17.0x, reducing fair value by 21.5%.3
Price-cost friction in Industrial Precision Solutions and unfavorable segment mix compression from lower-margin medical or industrial equipment shipments.
Current:25.49% operating margin in FY2025
Alert ifConsolidated operating margin falling below 22.5% of revenue
Market de-rating toward industrial peer median (e.g. OTIS at 14.57x) as organic growth moderates below compounder expectations.
Current:24.75x forward P/E as of 2026-10-11
Alert ifForward P/E multiple contracting below 17.0x
Escalating trade barriers, cross-border tariffs, or localized industrial stagnation impairing cross-border capital investment programs.
Current:Asia-Pacific ex-Japan $863.64M (30.9%) and Europe $722.22M (25.9%) of FY2025 revenue,
Alert ifRegional revenue contraction exceeding 10% YoY in either territory
Loss of manufacturing delivery lead-time advantage or market share erosion to peers across core industrial and medical dispensing end-markets,.
Current:12% overall organic growth in Q3 2026
Alert ifOrganic revenue growth slowing below 2.0% YoY
| Price-cost compression and product mix dilution across industrial segments | medium | 12-24 months | NBS Next operational improvements and disciplined pricing strategy target 35-40% incremental margins to offset raw material and wage inflation.4 |
| Tariff adjustments and cross-border trade friction impacting precision parts shipments | low | 24-36 months | Balanced manufacturing and technical service presence across the Americas ($1,205.83M), Asia-Pacific ($863.64M), and Europe ($722.22M) enables localized assembly and delivery,,.7 |
Under the moderate discount rate, $46.17 comes from forecast-period earnings and $171 from the long-term value, totaling $217.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows ($41.63) plus discounted terminal value ($134) minus signed per current share ($33.88) equals the $142 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Solve for the growth rate that makes the model value equal the report-date share price.
The Bull scenario represents a probability of 20.0% with a target valuation of $255.82, yielding an implied return of -22.0% against $328.17. In this trajectory, an extended semiconductor advanced packaging investment cycle accelerates high-margin equipment shipments in Advanced Technology Solutions, while medical fluid component adoption accelerates. Operating margins expand robustly as strong operating leverage delivers incremental margins at the top end of management targets. Disconfirmation of this optimistic path would occur if electronics packaging orders plateau or if customer capital expenditure budgets tighten across key manufacturing regions.
Tracking operating margins confirms whether NBS Next operational efficiencies and incremental margin targets can successfully offset wage inflation and product mix dilution.
Expansion in medical fluid components provides non-cyclical recurring revenue that stabilizes consolidated earnings when industrial and electronics manufacturing cycles soften.
Shorter delivery lead times relative to industrial competitors drive market share gains and protect pricing power without generating internal fulfillment bottlenecks.
Balanced geographic exposure insulates consolidated results against localized economic slowdowns, currency fluctuations, and regional trade policy shifts.
| $3.42B |
| $3.63B |
| $3.83B |
| Revenue growth | 9.5% | 5.1% | 6.5% | 6.0% | 5.5% |
| Operating margin | 25.8% | 26.0% | 26.2% | 26.4% | 26.5% |
| Operating income | $788.75M | $835.80M | $896.98M | $958.05M | $1.01B |
| Tax rate | 18.0% | 18.0% | 18.0% | 18.0% | 18.0% |
| NOPAT | $646.78M | $685.36M | $735.52M | $785.60M | $831.95M |
| Reinvestment | $116.42M | $123.36M | $132.39M | $141.41M | $149.75M |
| Reinvestment rate (of NOPAT) | 18.0% | 18.0% | 18.0% | 18.0% | 18.0% |
| Free cash flow to firm | $530.36M | $561.99M | $603.13M | $644.19M | $682.20M |
| Industrial Precisions Solutions revenue | $1.46B | $1.53B | $1.63B | $1.73B | $1.83B |
| Medical Fluid Systems revenue | $914.71M | $961.81M | $1.02B | $1.09B | $1.15B |
| Advanced Technology Systems revenue | $683.89M | $719.11M | $765.85M | $811.80M | $856.45M |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Nordson maintains a highly disciplined capital allocation framework. Modest annual capex requirements ($58.06M in FY2025, or 2.08% of revenue,) leave vast excess cash for debt reduction, progressive dividend distributions, and targeted strategic M&A. Long-term debt stood at $1,529.01M as of 2026-07-31, which is comfortably serviced by annual operating cash flows of $719.18M. Management continues to prioritize deleveraging and selective niche acquisitions that reinforce proprietary fluid technologies without diluting invested capital returns.
Consolidated FY2025 operating income reached $711.73M (25.49% operating margin), anchored by core IPS ($1,331.79M revenue), with management targeting 35-40% incremental margins across all segments.
Strong pricing power and operating leverage support high mid-20s operating margins, though price/cost dynamics in IPS require ongoing vigilance.
Management raised FY2026 guidance to sales of $3.04B-$3.08B and adjusted EPS of $11.80-$12.00,, in line with consensus projections of $3,057.30M sales and $11.95 EPS,.
Operational momentum is fully intact, but this reality is already more than priced into the $328.17 market quote.
| Margin |
|---|
| NDSN | Nordson Corporation | $18.3B | 24.8x | 6.1x | 20.8x | 17.8% | — |
| OTIS | Otis Worldwide Corporation | $25.1B | 14.6x | 1.7x | 12.7x | — | 15.1% |
| ROK | Rockwell Automation Inc. | $48.0B | 29.0x | 5.4x | 24.5x | 30.6% | 21.0% |
| ITW | Illinois Tool Works Inc. | $75.2B | 21.4x | 4.6x | 17.5x | 104.6% | 26.9% |
| GNRC | Generac Holdings Inc. | $13.3B | 17.3x | 3.0x | 22.6x | 9.5% | 17.9% |
| Global Manufacturing Nearshoring and Regional Supply Chain Reconfiguration | neutral | Multinational manufacturers reconfiguring production footprints between the US, Europe, and Asia-Pacific generate initial equipment re-tooling demand, but introduce interim project deferrals and supply chain tariff friction,. |
| Below 22.5% of revenue |
| Confirm the kill scenario; lower terminal operating margin assumption to 22.0%. |
| Forward P/E valuation multiple | Below 17.0x forward earnings | Re-assess peer multiple discount; evaluate whether market de-rating has restored adequate margin of safety. |
| Regional revenue contraction in Asia-Pacific or Europe | Contraction exceeding 10% YoY | Re-underwrite international trade friction exposure and reduce terminal growth rate to 2.0% in DCF model.7 |
| Consolidated organic revenue growth | Slowing below 2.0% YoY | Confirm erosion of NBS Next lead-time advantage; reduce forward revenue growth assumptions to 3.0% across valuation models.4 |
